Women's Health Diagnostics / Precision Pregnancy Care / In Vitro Diagnostics (IVD)
Strategic Profile
Sera leverages proprietary proteomics and bioinformatics platforms to build a pipeline of pregnancy-related biomarker tests including preeclampsia, fetal growth restriction, and gestational diabetes detection. The company is pursuing payer adoption through Medicaid pilots across multiple states while scaling from early commercialization toward market penetration in precision pregnancy care.
Cyborg Score Rationale
Sera has significant clinical validation (PRIME trial published Jan 2026 showing 20% reduction in NICU admissions) and ~$102M cash runway through 2028, but faces early commercialization stage challenges with minimal revenue ($16K Q3 2025) and ongoing losses ($7.8M net loss Q3). Path to profitability depends heavily on payer adoption and scaling.
Top Insights
PRIME trial (5,018 women) published Jan 2026 demonstrates PreTRM test reduces earliest preterm births and neonatal complications by 20% NICU reduction
Early payer engagement across 13 states with active Nevada Medicaid pilot and $100K deferred revenue showing pathway to reimbursement
Pre-revenue commercialization stage with minimal current sales ($16K Q3 2025) but adequate cash reserves ($102.4M) to fund operations through 2028
Competitive advantage in only broadly validated blood-based preterm birth predictor, addressing $15B+ global maternal health market opportunity
Named Competitors
Biodesix Technology — Precision diagnostics for lung and blood cancers
GRAIL Test — Blood-based cancer early detection
RareCyte Platform — Cell analysis and diagnostic imaging
Recent Developments
(January 2026) PRIME study published showing PreTRM test reduced earliest preterm births and newborn complications
(November 2025) Q3 2025 earnings: $16K revenue, $7.8M net loss, $102.4M cash position; Nevada Medicaid pilot active
(Late 2025) Dr. Tiffany Inglis appointed Chief Medical Officer to lead clinical operations and payer strategy
Open the full interactive Sera Prognostics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.